Relyvrio Falls Short of Primary Endpoint in Phase III PHOENIX Trial in Patients with ALS
Relyvrio did not significantly alter amyotrophic lateral sclerosis disease progression as measured by the ALSFRS-R total score at Week 48 compared to placebo.
August 16, 2026
Breaking News
Can an Office harassment lawyer negotiate a settlement? |
Why is Jack Bodenstein gaining attention? |
Which 100 Series Dash Mats offer the best fit and protection? |
Is oven repair Ottawa worth it for older electric and gas ovens? |
How often should organizations conduct a cloud penetration test? |
